Currently out of the existing stock ratings of Alan Carr, 59 are a BUY (95.16%), 2 are a SELL (3.23%), 1 are a HOLD (1.61%).

Alan Carr

Work Performance Price Targets & Ratings Chart

Analyst Alan Carr, currently employed carries an average stock price target met ratio of 60.69% that have a potential upside of 28.61% achieved within 227 days. Previously, Alan Carr worked at NEEDHAM.

Alan Carr’s has documented 138 price targets and ratings displayed on 18 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 13-May-2022.

Wall Street Analyst Alan Carr

Analyst best performing recommendations are on BHVN (BIOHAVEN PHARMACEUTICAL HOLDING CO LTD).
The best stock recommendation documented was for CARA (CARA THERAPEUTIC) at 2/27/2014. The price target of $22 was fulfilled within 6 days with a profit of $4.64 (26.73%) receiving and performance score of 44.55.

Average potential price target upside

of $114.8 (24.28%) on TTPH (TETRAPHASE PHARMACEUTICALS).
of $46.5 (95.96%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $24.63 (24.33%) on VRTX (VERTEX PHARMACEUTICALS).

CRSP Crispr Therapeutics AG GILD Gilead Sciences MRNA Moderna PHAT Phathom Pharmaceuticals VRTX Vertex Pharmaceuticals ACAD ACADIA Pharmaceuticals ALNY Alnylam Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd CARA Cara Therapeutic ICPT Intercept Pharmaceuticals LXRX Lexicon Pharmaceuticals TRVN Trevena TTPH Tetraphase Pharmaceuticals VIR Vir Biotechnology NBIX Neurocrine Biosciences RYTM Rhythm Pharmaceuticals VVUS VIVUS ZEAL Zealand Pharma A/S ADR

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Geulah Livshits (CHARDAN CAPITAL)